Public-private partnerships to revitalize psychiatric drug discovery

Expert Opinion on Drug Discovery

Volumn 9, Issue 1, 2014, Pages 1-8

  Brady, Linda S ^a   Potter, William Z ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Alzheimer's Disease Neuroimaging Initiative; Autism spectrum disorder; Biomarkers; Biomarkers Consortium; Cellular models; Consortia; Disease phenotyping; Major depressive disorder; Psychiatric drug discovery; Psychiatric genetics; Public private partnerships; Schizophrenia

Indexed keywords

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; DRUG DEVELOPMENT; EUROPE; GENETIC RISK; HUMAN; NEUROIMAGING; PIPELINE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PSYCHIATRY; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; UNITED STATES;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DISCOVERY; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84890472772     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.867944     Document Type: Review

References (41)

1. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet 2013;382(9904):1575-86
2. Hyman SE. Revolution stalled. Sci Transl Med 2012;4(155):155cm11
3. Insel TR. Next-generation treatments for mental disorders. Sci Transl Med 2012;4(155):155ps19
4. Alzheimer's Disease Neuroimaging Initiative (ADNI). Available from: Http://www.adni-info.org/
5. Foundation for the National Institutes of Health (FNIH). Available from: Http://www.fnih.org/work/nih
6. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 2013;9(5):e111-94. Review article providing a detailed summary of published research finding of ADNI since the inception of the program.
7. Biomarkers Consortium. Available from: Http://www.biomarkersconsortium. org/
8. Biomarkers Consortium, Neuroscience Steering Committee. Available from: Http://www.biomarkersconsortium.org/steering-neuro.php
9. Potter WZ, Pickering EH, Immerman F, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI), the Foundation for NIH Biomarkers Consortium CSF Proteomics Project Team. Cerebrospinal fluid (CSF) vs. plasma-based biomarkers in Alzheimer's disease (AD), mild cognitive impaired (MCI) and agematched healthy controls (HC) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Alzheimers Dement 2012;8(4):P217
10. Siuciak JA, Pickering EH, Immermann F, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI), the Foundation for NIH Biomarkers Consortium CSF Proteomics Project Team. Cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD), mild cognitively impaired (MCI) and age-matched healthy controls (HC) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Alzheimers Dement 2012;8(4):P216-P17
11. Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 2012;69(10):1310-17
12. NIH-Industry Pilot, Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses). Available from: Http://www.ncats.nih.gov/ research/reengineering/rescue-repurpose/therapeutic-uses/therapeutic-uses.html
13. Colvis CM, Devaney S, Brady LS, Hudson KL. Partnering for therapeutics discovery. Clin Pharmacol Ther 2013;93(1):24-5
14. Wadman M. NIH gambles on recycled drugs. Nature 2013;499(7458):263-4
15. Novel Methods Leading to New Medications in Depression and Schizophrenia (New Meds). Available from: Http://www.newmeds-europe.com/en/news.php
16. Goldman M. The innovative medicines initiative: A European response to the innovation challenge. Clin Pharmacol Ther 2012;91(3):418-25. An overview of the IMI and the projects conducted by the IMI consortia.
17. Rabinowitz J, Werbeloff N, Caers I, et al. Negative symptoms in schizophrenia-the remarkable impact of inclusion definitions in clinical trials and their consequences. Schizophr Res 2013;150(2-3):334-8. An analysis of data from the NewMeds repository examining the impact of operational criteria for negative symptoms on patient inclusion and outcome in schizophrenia trials.
18. Psychiatric Genomics Consortium. Available from: Https://pgc.unc.edu/
19. Psychiatric GWAS Consortium Steering Committee. A framework for interpreting genome-wide association studies of psychiatric disorders. Mol Psychiatry 2009;14(1):10-17
20. Lee SH, Ripke S, Neale BM, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013;45(9):984-94. A meta-analysis of genome-wide genotype data for cases and controls in schizophrenia, bipolar disorder, MDD, ASDs and ADHD conducted by the Cross-Disorder Group of the PGC.
21. National Cooperative Reprogrammed Cell Research Groups (NCRCRG) to Study Mental Illness. Available from: Http://grants.nih.gov/grants/guide/pa-files/PAR- 13-225.html
22. Panchision DM. Meeting report: Using stem cells for biological and therapeutics discovery in mental illness. Stem Cells Transl Med 2013;2(3):217-22
23. The Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95(4):629-35. An overview of the goals and objectives of the PPMI, an international, multicenter study to identify PD progression biomarkers.
24. P1vital. Available from: Http://www.p1vital.com/
25. Landau SM, Breault C, Joshi AD, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: Comparing radiotracers and quantification methods. J Nucl Med 2013;54(1):70-7
26. Critical Path Institute (C-Path). Available from: Http://c-path.org/
27. Coalition Against Major Diseases (CAMD). Available from:Http://c-path. org/programs/camd/
28. Patient-Reported Outcome (PRO). Available from: Http://c-path.org/ programs/pro/
29. Predictive Safety Testing Consortium (PSTC). Available from: Http://c-path. org/programs/pstc/
30. European Autism Interventions-A Multicentre Study for Developing New Medications (EU-AIMS). Available from: Http://www.eu-aims.eu/http://www.imi. europa.eu/content/eu-aims
31. Innovative Medicines Initiative (IMI). Available from: Http://www.imi.europa.eu/
32. Medical Research Council (MRC)/AstraZeneca Mechanisms of Disease Initiative. Available from: Http://www.mrc.ac.uk/Fundingopportunities/Calls/MoD/ MRC008389 http://www.astrazeneca.com/Media/Press-releases/Article/20121131- astrazeneca-MRCcollaboration-disease-research
33. National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19). Available from: Http://grants.nih.gov/grants/guide/pa-files/PAR-13-086.html
34. Functional Selectivity: A Novel Approach for CNS Drug Discovery. Available from: Http://projectreporter.nih.gov/project-info-description.cfm aid =8527845&icde=18333422 &ddparam=&ddvalue=&ddsub= &cr=3&csb=default&cs=ASC
35. Parkinson's Progression Markers Initiative (PPMI). Available from: Http://www.ppmi-info.org/
36. PharmaCog. Available from: Http://www.imi.europa.eu/content/pharma-cog http://www.alzheimer-europe.org/Research/PharmaCog
37. One Mind for Research. Available from: Http://1mind4research.org/
38. Structural Genomics Consortium (SGC). Available from: Http://www.thesgc.org/
39. Norman TC, Bountra C, Edwards AM, et al. Leveraging crowdsourcing to facilitate the discovery of new medicines. Sci Transl Med 2011;3(88):88mr1
40. NIH-Industry Target Validation Consortium. Available from: Http://www.ncats.nih.gov/research/reengineering/drugtargets/drug-targets.html
41. TRIMAGE. Available from: Http://ec. europa.eu/research/health/ medicalresearch/brain-research/projects/trimage-en.html